Navigation Links
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
Date:4/26/2013

MONROVIA, Calif., April 26, 2013 /PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for which MorphoSys licensed exclusive worldwide rights from Xencor in 2010. The dosing of the first patient in the study triggers an undisclosed milestone payment to Xencor.

The US-based study is an open-label, multicenter, single-arm clinical trial designed to assess the efficacy of MOR208 in patients suffering from relapsed or refractory B-ALL. Secondary outcome measures include response duration, safety and pharmacokinetics of MOR208. In total, 30 patients are planned to be enrolled. More information on the trial can be found by searching for MOR208 at www.clinicaltrials.gov.

"Preclinical and early clinical studies of MOR208 have shown promising anti-tumor activity and supported this additional study in ALL as well as another study in Non Hodgkin's Lymphoma which is expected to start shortly," said Bassil Dahiyat , Ph.D., Chief Executive Officer of Xencor. "Xencor monoclonal antibody candidates continue to advance in clinical development and showcase the value of our XmAb® Fc technology."

MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition to the phase 2 trial in B-ALL MorphoSys is about to start a second Phase 2 trial in Non-Hodgkin's Lymphoma (NHL).

B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and fifty thousand patients in the seven major markets each year. The target molecule CD19
'/>"/>

SOURCE Xencor
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Clinical trial for rabies monoclonal antibody
2. New monoclonal antibody developed that can target proteins inside cancer cells
3. Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis
4. Flu antibody’s one-handed grab may boost effort toward universal vaccine, new therapies
5. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
6. Labor der Zukunft -- Tomorrows laboratory technology
7. The future of plant science - a technology perspective
8. The future of plant science a technology perspective
9. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
10. UF researchers look for ways to make an emerging technology safe for environment
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... before 4 months of age and after 6 months may ... of Colorado researchers have found. The researchers, from the ... Medicine,s Barbara Davis Center for Diabetes, also found that the ... baby when solid foods, particularly those containing wheat or barley, ...
... indicate that our close cousins, the Neandertals, were much more ... did they have anything like modern speech and language? And ... diversity? The MPI for Psycholinguistics researchers Dan Dediu and Stephen ... Language Sciences that modern language and speech can be ...
... a better way to detect heat loss in electric-vehicle ... developed or advanced at the Energy Department,s National Renewable ... year,s most significant innovations by R&D Magazine. "These ... and energy efficiency demonstrate how NREL research produces results ...
Cached Biology News:Infants' food linked to higher, lower Type 1 diabetes risk 2Did Neandertals have language? 2NREL research earns 3 prestigious R&D 100 Awards 2NREL research earns 3 prestigious R&D 100 Awards 3NREL research earns 3 prestigious R&D 100 Awards 4
(Date:3/3/2015)... 2015  Regenicin, Inc. (OTC Bulletin Board: ... of and commercialization of regenerative cell therapies to restore ... that it has received the final payment to conclude ... (OTC Bulletin Board: AMBS ). ... final payments due to Regenicin in the amount of ...
(Date:3/3/2015)... The winners of awards for supply ... the Global Supply Chain Resiliency Council (GSCRC) ... Wednesday, February 25th, 2015, at the Hyatt Regency in ... bring together supply chain risk management and resiliency practitioners ... discipline through opportunities to collaborate, develop and share best ...
(Date:3/3/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or ... Expert Opinion on Biological Therapy , Dr. Michael ... , at the Henry Ford Hospital in ... (TB4) has the capacity to promote CNS and peripheral ... leading to neurological recovery in each case.  They pointed ...
(Date:3/3/2015)... , March 3, 2015  Rosa & Co. ... drug-disease modeling and simulation research, today announced it has ... American Society for Clinical Pharmacology and Therapeutics meeting in ... 2015.   Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... will present a poster describing a quantitative systems pharmacology ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... Senior Vice President, Commercial Development, NASHVILLE, ... appointed industry veteran Martin E. Cearnal as ... created position Mr.,Cearnal will be directly involved ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080903/CLW115 ), ...
... 3 US Oncology Specialty, LP, the,state-of-the-art pharmaceutical ... Excellence Achievement Award from the National,Safety Council for ... presented to companies who produce the "best of ... eligible, organizations must report,days away from work resulting ...
... Sept. 3 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ... technology, ePRO and other services to the pharmaceutical,biotechnology, ... Michael J. McKelvey, the Company,s President and Chief ... Officer, are,scheduled to present at the Thomas Weisel ...
Cached Biology Technology:Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position 2US Oncology Pharmaceutical Distribution Service Wins National Safety Council Award 2eResearchTechnology, Inc. to Present at the Thomas Weisel Healthcare Conference on September 4th, 2008 2
nuclear RNA export factor 1, mRNA...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
... ultimate in utility and flexibility press-to-seal silicone ... needs of the researcher. They are available ... as sheet material that can be easily ... are autoclavable and non-cytotoxic and can be ...
Biology Products: